## Contents

### Part I  Therapy-Derived Systems Biology:  
A Pragmatic Communication Theory

1  Bridging Theory and Therapeutic Practice:  
From Generalized Disease Models to Particular Patients ..................... 3  
Albrecht Reichle

2  Tumor Systems Need to be Rendered Usable for a New  
Action-Theoretical Abstraction: The Starting Point for  
Novel Therapeutic Options .............................................................. 9  
Albrecht Reichle

3  Principles of Modular Tumor Therapy ............................................ 29  
Albrecht Reichle and Gerhard C. Hildebrandt

### Part II  Tumors Share Common Processes During Tumor Evolution:  
Communicative Aspects of a Situation’s Interpretation for  
Creating Systems-Directed Therapies

4  Cancer and Coagulation; Focusing on Tissue  
Factor and Heparanase ........................................................................ 51  
Yona Nadir

5  The Role of Mesenchymal Cells in Cancer: Contribution  
to Tumor Stroma and Tumorigenic Capacity ...................................... 75  
Ofer Shoshani and Dov Zipori

6  Shaping Tumor Associated Macrophages: The Role of NF-κB .......... 97  
Robin Soper and Thorsten Hagemann

7  The Metabolic Achilles Heel: Tumor Cell Metabolism  
as Therapeutic Target ........................................................................ 111  
Eva Gottfried, Katrin Peter, and Marina P. Kreutz
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>Could Be Systems-Directed Therapy Approaches Promising in Glioblastoma Patients?</td>
<td>133</td>
</tr>
<tr>
<td></td>
<td>Oliver Grauer and Peter Hau</td>
<td></td>
</tr>
<tr>
<td>Part III</td>
<td>Systems-Relevant Molecular and Cellular Targets: Implementation of Modular ‘Knowledge’</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Functional Impacts of Signal Integration: Regulation of Inflammation-Related Transcription Factors by Heterotrimeric G Proteins</td>
<td>161</td>
</tr>
<tr>
<td></td>
<td>Wendy Wing Shan Yeung, Maurice Kwok Chung Ho, and Yung Hou Wong</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Molecular Cross-Talk Between Nuclear Receptors and Nuclear Factor-κB</td>
<td>191</td>
</tr>
<tr>
<td></td>
<td>Ilse M.E. Beck, Guy Haegeman, and Karolien De Bosscher</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>The Biomodulatory Capacities of Low-Dose Metronomic Chemotherapy: Complex Modulation of the Tumor Microenvironment</td>
<td>243</td>
</tr>
<tr>
<td></td>
<td>Urban Emmenegger, Annabelle Chow, and Guido Bocci</td>
<td></td>
</tr>
<tr>
<td>Part IV</td>
<td>Tumors are Evolvable Modular and Rationalized Systems: From Molecular to Modular Tumor Therapy</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Systems Biology: A Therapeutic Target for Tumor Therapy</td>
<td>265</td>
</tr>
<tr>
<td></td>
<td>Albrecht Reichle and Thomas Vogt</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>The Comparative Uncovering of Tumor Systems Biology by Modularly Targeting Tumor-Associated Inflammation</td>
<td>287</td>
</tr>
<tr>
<td></td>
<td>Albrecht Reichle and Gerhard C. Hildebrandt</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Searching for the ‘Metabolism’ of Evolution</td>
<td>305</td>
</tr>
<tr>
<td></td>
<td>Albrecht Reichle and Gerhard C. Hildebrand</td>
<td></td>
</tr>
<tr>
<td>Part V</td>
<td>Biomodulatory Therapy Approaches in Metastatic Cancer</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>The Impact of Inflammation Control and Active Cancer Palliation on Metabolic Pathways Determining Tumor Progression and Patient Survival</td>
<td>313</td>
</tr>
<tr>
<td></td>
<td>Ulrika Smedh, Annika Gustafsson, Hans Axelsson, Christian Cahlin, Christina Lönnroth, and Kent Lundholm</td>
<td></td>
</tr>
</tbody>
</table>
16 Pioglitazone and Rofecoxib Combined with Angiostatically Scheduled Capecitabine in Far-Advanced Hepatobiliary Carcinoma .......................... 341
Albrecht Reichle, Frank Klebl, Klaus Bross, Frank Kullmann, Peter Wild, Anna Berand, Stefan W. Krause, Jürgen Schölmerich, and Reinhard Andreesen

17 C-Reactive Protein As a Secretome-Derived Biomarker for Predicting Response to Biomodulatory Therapy in Metastatic Renal Clear Cell Carcinoma .......................................................... 353
Bernhard Walter, Irmela Schrettenbrunner, Martin Vogelhuber, Jochen Grassinger, Klaus Bross, Jochen Wilke, Thomas Suedhoff, Anna Berand, Wolf-Ferdinand Wieland, Sebastian Rogenhofer, and Albrecht Reichle

18 Modular Therapy Approach in Metastatic Castration-Resistant Prostate Cancer ............................................................. 367
Bernhard Walter, Sebastian Rogenhofer, Martin Vogelhuber, Jochen Wilke, Anna Berand, Walter Ferdinand Wieland, Reinhard Andreesen, and Albrecht Reichle

19 Systems-Directed Therapy in Metastatic Castration-Resistant Prostate Cancer (CRCP) .................................................................. 379
Albrecht Reichle, Martin Vogelhuber, Anna Berand, Reinhard Andreesen, Irene Fackler-Schwalbe, Annemarie Rübel, and Thomas Südhoff

Part VI Criteria for Checking Systems Behavior and Creating Predictions: Systems-Associated Biomarkers and Molecular Imaging

20 Early Detection of Systems Response: Molecular and Functional Imaging of Angiogenesis .................................................. 385
Fabian Kiessling and Wiltrud Lederle

21 Secretome Proteomics, a Novel Tool for Biomarkers Discovery and for Guiding Biomodulatory Therapy Approaches ......................... 405
Verena Paulitschke, Rainer Kunstfeld, and Christopher Gerner

22 Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma ......................................................... 433
Stefanie Meyer, Thomas Vogt, Michael Landthaler, Anna Berand, Albrecht Reichle, Frauke Bataille, Andreas Marx, Guido Sauter, Arndt Hartmann, Leoni Kunz-Schughart, and Peter J. Wild
Part VII  Pharmacological Considerations on Systems Biological Therapy Approaches

23  Uncovering Tumor Systems Biology by Biomodulatory Therapy Strategies .................................................. 469
    Albrecht Reichle

24  Breathing New Life into Old Drugs: Indication Discovery by Systems Directed Therapy ............................ 483
    Annika Bundscherer and Christian Hafner

Part VIII  Tumors' Systems Biology: Implications for Personalized Therapy

25  A Methodological Approach to Personalized Therapies in Metastatic Cancer ............................................ 507
    Albrecht Reichle, Thomas Vogt, and Gerhard C. Hildebrandt

Part IX  Summary

26  To Be an Object in a Biological System: The Necessity of a Formal-Pragmatic Communication Theory .................................................. 537
    Albrecht Reichle and Gerhard C. Hildebrandt

27  From Molecular to Modular, from Theme-Dependent to Evolution-Adjusted Tumor Therapy ........................................ 545
    Albrecht Reichle and Gerhard C. Hildebrandt

Index .................................................................................................................................................. 557
From Molecular to Modular Tumor Therapy: Tumors are Reconstructible Communicatively Evolving Systems
Reichle, A. (Ed.)
2010, VIII, 568 p., Hardcover